Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 5 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides - there is growing evidence that medicinal cannabis can benefit patients in a variety of clinical settings. based on this, the lgp classic oil range including 10:10 lgp classic, and 20:5 lgp classic as medicinal cannabis products, may have a role in medical conditions including: ? intractable chronic pain insufficiently responsive to other analgesics ? pain associated with spasticity in multiple sclerosis ? pain associated with cancer in palliative care ? cancer treatment-induced nausea and vomiting ? appetite loss ? insomnia ? post-traumatic stress disorder ? cachexia

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - cannabidiol, quantity: 10 mg/ml; tetrahydrocannabinol, quantity: 10 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides - there is growing evidence that medicinal cannabis can benefit patients in a variety of clinical settings. based on this, the lgp classic oil range as medicinal cannabis products may have a role in medical conditions including: ? intractable chronic pain insufficiently responsive to other analgesics ? pain associated with spasticity in multiple sclerosis ? pain associated with cancer in palliative care ? cancer treatment-induced nausea and vomiting ? appetite loss ? insomnia ? post-traumatic stress disorder ? cachexia

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - cannabidiol, quantity: 20 mg/ml; tetrahydrocannabinol, quantity: 1 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides - there is growing evidence that medicinal cannabis can benefit patients in a variety of clinical settings. based on this, the lgp classic oil range including 10:10 lgp classic, and 20:5 lgp classic as medicinal cannabis products, may have a role in medical conditions including:behavioural issues associated with autism, ? intractable epileptic seizures in adults and children, ? intractable chronic pain insufficiently responsive to other analgesics ? pain associated with spasticity in multiple sclerosis ? pain associated with cancer in palliative care ? cancer treatment-induced nausea and vomiting ? appetite loss ? insomnia ? post-traumatic stress disorder ? cachexia

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - 62001 - oral/enteral syringe, reusable - this device is intended to be used for the administration of oral medication. it consists of a calibrated hollow barrel (cylinder), made of plastic and a moveable plunger. the tip is designed to mate only with enteral administration devices. it is colour-coded to distinguish it from other syringes. this is a reusable device after appropriate cleaning.

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - 37428 - connector, - a device intended to allow a syringe to connect to a bottle so that they mate creating an entity.

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - 16825 - syringe tip cap - syringe tip cap that is used to cover the tip of a syringe to prevent the leakage of syringe contents

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 20 mg/ml; cannabidiol, quantity: 5 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides - there is growing evidence that medicinal cannabis can benefit patients in a variety of clinical settings. based on this, the lgp classic oil range including 10:10 lgp classic, and 20:5 lgp classic as medicinal cannabis products, may have a role in medical conditions including:? intractable chronic pain insufficiently responsive to other analgesics;? pain associated with spasticity in multiple sclerosis;? pain associated with cancer in palliative care;? cancer treatment-induced nausea and vomiting;? appetite loss;? insomnia;? post-traumatic stress disorder ? cachexia

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 10 mg/ml; cannabidiol, quantity: 10 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides - there is growing evidence that medicinal cannabis can benefit patients in a variety of clinical settings. based on this, lgp classic oil range as medicinal cannabis products may have a role in medical conditions including: ? intractable chronic pain insufficiently responsive to other analgesics ? pain associated with spasticity in multiple sclerosis;? pain associated with cancer in palliative care;? cancer treatment-induced nausea and vomiting;? appetite loss;? insomnia? post-traumatic stress disorder;? cachexia

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 1 mg/ml; cannabidiol, quantity: 20 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides - there is growing evidence that medicinal cannabis can benefit patients in a variety of clinical settings. based on this, the lgp classic oil range including 1:20 lgp classic, as a medicinal cannabis product, may have a role in medical conditions including: ? intractable epileptic seizures in adults and children, ? intractable chronic pain insufficiently responsive to other analgesics ? pain associated with spasticity in multiple sclerosis ? pain associated with cancer in palliative care ? cancer treatment-induced nausea and vomiting ? appetite loss ? insomnia ? post-traumatic stress disorder ? cachexia

Australia - English - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - cannabidiol, quantity: 50 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides - 1intractable chronic pain insufficiently responsive to other analgesics 2. pain associated with spasticity in multiple sclerosis (ms) 3. pain associated with cancer in palliative care 4. cancer treatment-induced nausea and vomiting 5. appetite loss 6. insomnia 7. post-traumatic stress disorder (ptsd) 8. cachexia 9. anxiety 10. refractory epilepsy